The NGS based CDx Human NTRK1/2/3 Genomic Alteration Test Kit to inform treatment decisions for larotrectinib developed by OrigiMed in cooperation with Bayer was granted the NMPA Special Review Procedure for Innovative Medical Devices in China
The companion diagnostic (CDx) Human Neurotrophic Tyrosine Receptor Kinase (NTRK) 1/2/3 Genomic Alteration Testing Kit developed by OrigiMed in cooperation with Bayer is granted the Special Review Procedure for Innovative Medical Devices by the National Medical Products Administration…
Comments Off on The NGS based CDx Human NTRK1/2/3 Genomic Alteration Test Kit to inform treatment decisions for larotrectinib developed by OrigiMed in cooperation with Bayer was granted the NMPA Special Review Procedure for Innovative Medical Devices in China